Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease

Renal Failure

Volumn 31, Issue 10, 2009, Pages 928-932

  Sengul, Erkan ^a   Sahin, Tayfun ^a   Sevin, Erce ^a   Yilmaz, Ahmet ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Aldosterone; Chronic kidney disease; Hyperkalemia; Proteinuria; Renoprotection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; POTASSIUM; SPIRONOLACTONE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MALE; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT OUTCOME; URINARY EXCRETION;

ADULT; ALDOSTERONE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE;

EID: 73649110263     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903216121     Document Type: Article

References (20)

1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869. (Pubitemid 34940825)
2. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
3. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care. 2003;26:2268-2274.
4. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
5. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1-9.
6. Brown NJ. Aldosteron and end-organ damage. Curr Opin Nephrol Hypertens. 2005;14:235-241.
7. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-68.
8. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensinaldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936-1939.
9. Delyani JA. Mineralocorticoid receptor antagonists. The evolution of utility and pharmacology. Kidney Int. 2000;57: 1408-1411.
10. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992-999. (Pubitemid 36359280)
11. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effect of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care. 2005;28:2106-2112.
12. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis. 2005;46:45-51.
13. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44-49.
14. Van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006; 24: 2285-2292.
15. Wakisaka M, Spiro MJ, Spiro RG. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IVcollagen. Diabetes. 1994;43:95-103.
16. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
17. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 1309-1321.
18. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351: 543-551.
19. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: Retrospective study. BMJ. 2003;327:1141-1142.
20. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med. 2001;110:438-441.